Is melatonin synthesis a new biomarker for the pathogenesis and treatment of phenylketonuria?
- PMID: 23312686
- PMCID: PMC4327885
- DOI: 10.1016/j.jpeds.2012.11.079
Is melatonin synthesis a new biomarker for the pathogenesis and treatment of phenylketonuria?
Conflict of interest statement
S.C. has served as a consultant to Biomarin, a company that produces Kuvan for the treatment of some patients with phenylketonuria. All proceeds from this consultancy have been given to philanthropic causes. H.L. declares no conflicts of interest.
Comment on
-
Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker.J Pediatr. 2013 May;162(5):999-1003. doi: 10.1016/j.jpeds.2012.10.015. Epub 2012 Nov 16. J Pediatr. 2013. PMID: 23164313 Free PMC article. Clinical Trial.
References
-
- Scriver CR, Clow CL. Phenylketonuria: epitome of human biochemical genetics. N Engl J Med. 1980;303:1336–1342. 1394–1400. - PubMed
-
- Lou HC. Dopamine precursors and brain function in phenylalanine hydroxylase deficiency. Acta Paediatr Suppl. 1994;407:86–88. - PubMed
-
- Baskett JJ, Cockrem JF, Antunovich TA. Sulphoxymelatonin in older people: relationship to plasma melatonin and renal function. J Pineal Res. 1998;24:58–61. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
